BioSpace News Archive

Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it has completed its public offering of 3,152,712 shares of its common stock.

Groupware Technology, Inc. announced it is the recipient of the Corporate Breath Award from the Northern California Chapter of the Cystic Fibrosis Foundation.

MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed.

Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that on January 24, 2020, the U.S. Food and Drug Administration (“FDA”) issued a “MINOR” Complete Response Letter (“CRL”) for its Abbreviated New Drug Application (“ANDA”) for Epinephrine Injection, USP 30mg/30mL (1mg/mL) Multiple Dose.

Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) and Histogen Inc., a privately-held regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, today announced the companies have entered into a definitive agreement under which Histogen will merge with a wholly-owned subsidiary of Conatus in an all-stock transaction.

Brooks Automation, Inc. (Nasdaq: BRKS) will announce fiscal 2020 first quarter earnings which ended December 31, 2019, on Thursday, February 6, 2020 after the market closes.

Teva Pharmaceuticals USA, Inc. an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the Food and Drug Administration (FDA) has approved an autoinjector device for AJOVY® (fremanezumab-vfrm) injection.

Elanco Animal Health Incorporated will announce its 2019 fourth quarter financial results on Wednesday, February 19, 2020.

Covalon Technologies Ltd., an advanced medical technologies company, announces its fiscal 2019 year-end results and plans for fiscal 2020.

Taro Pharmaceutical Industries Ltd. announced that it plans to release its financial results for the quarter and nine months ended December 31, 2019, after the close of market on Monday, February 3, 2020.